

PATENT  
674523-2006.1**AMENDMENT**

Please amend the application without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows:

**In the Claims**

- 1-8. (Cancelled)
9. (Currently amended) A retroviral vector derived from a [lentivirus genome wherein the] non-primate lentivirus genome, which lacks the *tat* gene but includes the leader sequences between the end of the 5' LTR and the ATG of *gag*.
10. (Currently amended) [A] The retroviral vector according to claim 9, which comprises at least one component from an [equinine] equine lentivirus.
11. (Currently amended) [A] The retroviral vector according to claim 10, wherein the [equinine] equine lentivirus is EIAV.
12. (Currently amended) [A] The retroviral vector according to claim 11, wherein the retroviral vector is substantially derived from EIAV.
- 13-14. (Cancelled)
15. (Original) A hybrid viral vector system comprising a primary viral vector derived from a poxvirus and a second viral vector derived from a retrovirus.
16. (Currently amended) A retroviral particle obtainable from the retroviral vector of claim 9 [or 15].
17. (Currently amended) A cell transfected or transduced with a [retroviral vector according to the] retroviral particle obtainable from the retroviral vector of claim 9 [or 15].
18. (Currently amended) A cell transfected or transduced with a retroviral vector according to claim 9 [or 15].
19. (Cancelled)
20. (Currently amended) A method for delivery of a nucleotide sequence of interest (NOI) to a target cell comprising introducing the [Use of a] retroviral vector according to claim 9 into the target cell, wherein the retroviral vector comprises an NOI, and [or 15 for the manufacture of a pharmaceutical composition to deliver an NOI to a target site] whereby the NOI is expressed in the target cell.
21. (Currently amended) A method [comprising] of transfecting or transducing a cell,

PATENT  
674523-2006.1

~~comprising contacting said cell with [a] the retroviral vector according to claim 9 [or 15],  
wherein said cell is transfected or transduced by said retroviral vector.~~

22. (Currently amended) A delivery system in the form of a retroviral vector according claim 9 [or 15].

23. (Currently amended) A delivery system for a retroviral vector according to claim [9 or] 15, wherein the delivery system comprises a non-retroviral expression vector, an adenovirus and/or a plasmid.

24. (Currently amended) A retroviral vector production system comprising the retroviral vector of claim 9 [substantially as hereinbefore described with reference to the accompanying Figures].

25-29. (Cancelled)

---